knee osteoarthritis
Conditions
Interventions
Orally soluble pellicles (OSP) of ondansetron: Patients in the OSP ondansetron group (Group 2) received 16mg ondansetron at 1 hour before anesthesia induction, and 8mg twice daily on postoperative day
intravenous ondansetron:Patients in the IV ondansetron group (Group 3) received 8mg ondansetron at anesthesia induction and 8mg once daily on postoperative day 1 and 2.
Sponsors
West China Hospital,SCU
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients aged 40 to 80 years who received their first unilateral TJA for primary hip or knee osteoarthritis were enrolled in the trial.
Exclusion criteria
Exclusion criteria: The exclusion criteria were any one of the following: (1) history of allergy to study drugs, (2) use of systemic steroids or antiemetics within 24 hours preoperative, (3) a history of steroid or immunosuppressive drug use within the first 6 months, (4) a history of gastrointestinal disease, such as reflux esophagitis, gastroduodenal ulcer, or severe impairment of gastrointestinal motility, (5) poor control of blood glucose and blood pressure; (6) Combining other diseases such as Meniere syndrome that may cause nausea and vomiting; (7) participating in other trials or is expected to have insufficient compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| postoperative nausea and vomiting; | — |
Secondary
| Measure | Time frame |
|---|---|
| inflammatory biomarkers;the dosage of metoclopramide;the dosage of tramadol;common adverse drug reactions (ADRs) associated with serotonin receptor antagonists, namely pruritus, dizziness, headache, cardiac arrhythmias, and extrapyramidal signs; | — |
Countries
China
Contacts
Public ContactJinwei XIe
West China Hospital,SCU
Outcome results
None listed